Skip to Content

Join the 'Addyi' group to help and get support from people like you.

Addyi News

'Female Libido' Pill May Not Be Worth It: Researchers

Posted 29 Feb 2016 by Drugs.com

MONDAY, Feb. 29, 2016 – The much-touted "female libido" pill seems to cause a host of serious side effects while failing to spark much additional passion in a woman's life, a new review suggests. Addyi (flibanserin) quadruples the risk of dizziness and sleepiness, more than doubles the chances of nausea, and increases the risk of fatigue by more than half, according to the analysis. For all that trouble, a woman taking Addyi can expect to gain one-half of one additional satisfying sexual event per month, on average, according to the report. It was published online Feb. 29 in the journal JAMA Internal Medicine. "We found women had, on average, 2.5 satisfying sexual events per month before entering the study, and flibanserin added one-half additional satisfying sexual events per month," said senior study author Ellen Laan, a professor of sexology and psychosomatic gynecology at the ... Read more

Related support groups: Sleep Disorders, Nausea/Vomiting, Fatigue, Sexual Deviations or Disorders, Addyi, Hypoactive Sexual Desire Disorder, Flibanserin

Pill for Low Libido in Women Goes on Sale on Saturday

Posted 16 Oct 2015 by Drugs.com

FRIDAY, Oct. 16, 2015 – The so-called "little pink pill" – the controversial drug intended to boost flagging sex drive in women – goes on sale on Saturday. Flibanserin (Addyi) is the first U.S. Food and Drug Administration-approved drug designed to help women with low libido. But that approval, announced in August, came with significant restrictions because the drug can cause severely low blood pressure and loss of consciousness, the FDA warned. Addyi's label will include a boxed warning saying the drug shouldn't be taken while drinking alcohol, and shouldn't be used with certain other drugs and by women with liver problems. And the once-daily pill, to be taken at night, can only be prescribed or dispensed by doctors and pharmacists who have been thoroughly briefed on the drug and its benefits and risks, the FDA added. "Today's approval provides women distressed by their low sexual ... Read more

Related support groups: Addyi, Sexual Deviations or Disorders, Hypoactive Sexual Desire Disorder, Flibanserin

FDA Approves Addyi (flibanserin) for Hypoactive Sexual Desire Disorder in Premenopausal Women

Posted 19 Aug 2015 by Drugs.com

August 18, 2015 - The U.S. Food and Drug Administration today approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Prior to Addyi’s approval, there were no FDA-approved treatments for sexual desire disorders in men or women. “Today’s approval provides women distressed by their low sexual desire with an approved treatment option,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER). “The FDA strives to protect and advance the health of women, and we are committed to supporting the development of safe and effective treatments for female sexual dysfunction.” HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a m ... Read more

Related support groups: Addyi, Hypoactive Sexual Desire Disorder, Flibanserin

Addyi Female Libido Pill Now FDA Approved

Posted 19 Aug 2015 by Drugs.com

WEDNESDAY, Aug. 19, 2015 – Addyi (flibanserin) has been approved by the U.S. Food and Drug Administration as the first drug to treat low sexual desire among premenopausal women. The drug is for women who do not have an underlying physical or psychological cause for the disorder, the agency said in a news release. Addyi's label will warn that it can cause blood pressure to drop severely and may lead to loss of consciousness. These risks increase and symptoms may become worse when alcohol is consumed. So, Addyi users are warned to not to drink any alcohol, the FDA said. Doctors who prescribe the drug and any pharmacy that dispenses it must be certified, the agency said. Pharmacies must warn users of the risks of drinking alcohol while on the medication. People who take the once-daily drug should discontinue use after eight weeks if there's no improvement in sexual desire, the FDA added. ... Read more

Related support groups: Addyi, Hypoactive Sexual Desire Disorder, Flibanserin

Ask a Question

Further Information

Related Condition Support Groups

Hypoactive Sexual Desire Disorder

Addyi Patient Information at Drugs.com